Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Anemia 39 Neoplasms 19 Breast Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma 5 Neoplasms, Plasma Cell 4 Multiple Myeloma 4 Lung Neoplasms 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Leukemia 4 Waldenstrom Macroglobulinemia 3 Sezary Syndrome 3 Prostatic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precancerous Conditions 3 Mycosis Fungoides 3 Monoclonal Gammopathy of Undetermined Significance 3 Lymphoproliferative Disorders 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Follicular 3 Leukemia, Prolymphocytic 3 Leukemia, Large Granular Lymphocytic 3 Immunoglobulin Light-chain Amyloidosis 3 Immunoblastic Lymphadenopathy 3 Hodgkin Disease 3 Hematologic Neoplasms 3

Interventions

Darbepoetin alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Primary Care × Darbepoetin alfa × Clear all

NCT07130487 2025-11-25

Project CARE: CAncer Risk Evaluation

Rutgers, The State University of New Jersey

Phase NA Recruiting

Primary Care

Data powered by HemOnc (CC BY 4.0) Colophon ⚡